Abingdon Health Plc
ABDX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.39 | 0.12 | -3.65 |
| FCF Yield | -13.37% | -5.44% | 2.32% | -26.48% |
| EV / EBITDA | -7.94 | -33.67 | -12.19 | -1.55 |
| Quality | ||||
| ROIC | -54.28% | -36.84% | -89.67% | -154.57% |
| Gross Margin | 37.11% | 59.97% | 34.66% | -184.44% |
| Cash Conversion Ratio | 0.91 | 1.31 | -0.29 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.73% | 29.35% | -29.65% | -18.49% |
| Free Cash Flow Growth | -101.88% | -301.18% | 109.95% | 57.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.43 | 0.79 | 0.06 |
| Interest Coverage | -53.67 | -24.09 | -51.28 | -175.43 |
| Efficiency | ||||
| Inventory Turnover | 10.08 | 5.57 | 8.03 | 15.10 |
| Cash Conversion Cycle | 99.86 | 40.06 | -8.92 | 985.82 |